300122 智飞生物
已收盘 07-03 15:00:00
资讯
新帖
简况
智飞生物：公司持续加快产品创新，强化核心竞争力
证券之星 · 07-03 17:06
智飞生物：公司持续加快产品创新，强化核心竞争力
智飞生物：公司2026年半年度报告预约于2026年8月18日披露
证券之星 · 07-03 17:01
智飞生物：公司2026年半年度报告预约于2026年8月18日披露
智飞生物：公司已经根据法规要求制定了《市值管理制度》
证券之星 · 07-03 16:57
智飞生物：公司已经根据法规要求制定了《市值管理制度》
智飞生物：自去年以来，公司采取一系列措施促进公司生产经营稳健发展
证券之星 · 07-03 16:48
智飞生物：自去年以来，公司采取一系列措施促进公司生产经营稳健发展
智飞生物（300122）披露控股股东部分股份补充质押公告，6月26日股价下跌5.17%
证券之星 · 06-26
智飞生物（300122）披露控股股东部分股份补充质押公告，6月26日股价下跌5.17%
6月26日智飞生物跌5.17%，疫苗ETF嘉实基金重仓该股
证券之星 · 06-26
6月26日智飞生物跌5.17%，疫苗ETF嘉实基金重仓该股
股市必读：智飞生物（300122）6月18日董秘有最新回复
证券之星 · 06-22
股市必读：智飞生物（300122）6月18日董秘有最新回复
智飞生物：目前该计划正常存续中并且为公司股东
证券之星 · 06-18
智飞生物：目前该计划正常存续中并且为公司股东
智飞生物：公司积极响应国家号召推进互联网+医疗服务
证券之星 · 06-18
智飞生物：公司积极响应国家号召推进互联网+医疗服务
智飞生物：公司的在售产品有ACYW135多糖疫苗、23价肺炎疫苗、四价流感疫苗、九价HPV疫苗、重组带状疱疹疫苗等产品
证券之星 · 06-18
智飞生物：公司的在售产品有ACYW135多糖疫苗、23价肺炎疫苗、四价流感疫苗、九价HPV疫苗、重组带状疱疹疫苗等产品
智飞生物(300122.SZ)：重组轮状病毒亚单位疫苗(大肠杆菌)临床试验申请获得受理
智通财经 · 06-18
智飞生物(300122.SZ)：重组轮状病毒亚单位疫苗(大肠杆菌)临床试验申请获得受理
智飞生物：截至2026年5月29日，公司普通股股东人数为115,077
证券之星 · 06-05
智飞生物：截至2026年5月29日，公司普通股股东人数为115,077
智飞生物：2025年度研发投入达14.36亿元
证券之星 · 06-05
智飞生物：2025年度研发投入达14.36亿元
智飞生物：公司自去年以来采取一系列措施促进公司生产经营稳健发展
证券之星 · 06-05
智飞生物：公司自去年以来采取一系列措施促进公司生产经营稳健发展
智飞生物：防未病治已病，守护人类健康
证券之星 · 06-05
智飞生物：防未病治已病，守护人类健康
智飞生物：公司利拉鲁肽注射液、德谷胰岛素注射液两款产品处于上市审评阶段
证券之星 · 06-05
智飞生物：公司利拉鲁肽注射液、德谷胰岛素注射液两款产品处于上市审评阶段
智飞生物：公司以“技术&市场”双轮驱动发展
证券之星 · 06-05
智飞生物：公司以“技术&市场”双轮驱动发展
智飞生物（300122）披露2025年年度股东会决议公告，6月2日股价下跌2.7%
证券之星 · 06-02
智飞生物（300122）披露2025年年度股东会决议公告，6月2日股价下跌2.7%
股市必读：智飞生物（300122）5月29日董秘有最新回复
证券之星 · 06-01
股市必读：智飞生物（300122）5月29日董秘有最新回复
智飞生物：15价肺炎结合疫苗目前处于上市审评阶段
证券之星 · 05-29
智飞生物：15价肺炎结合疫苗目前处于上市审评阶段
加载更多
公司概况
公司名称：
重庆智飞生物制品股份有限公司
所属行业：
医药制造业
上市日期：
2010-09-28
主营业务：
重庆智飞生物制品股份有限公司的主营业务是疫苗、生物制品研发、生产、销售、推广、配送及进出口。公司的主要产品是盟威克、盟纳康、喜菲贝、盟纳克、智克威得、宜卡、微卡、优威克、四价流感病毒裂解疫苗、佳达修、佳达修9、乐儿德、纽莫法、维康特、欣安立适。
发行价格：
37.98
{"stockData":{"symbol":"300122","market":"SZ","secType":"STK","nameCN":"智飞生物","latestPrice":12.17,"timestamp":1783062186000,"preClose":12.17,"halted":0,"volume":25177465,"delay":0,"changeRate":0,"floatShares":1414000000,"shares":2394000000,"eps":-6.1778,"marketStatus":"已收盘","change":0,"latestTime":"07-03 15:00:00","open":12.22,"high":12.45,"low":11.99,"amount":307000000,"amplitude":0.0378,"askPrice":12.18,"askSize":107,"bidPrice":12.17,"bidSize":747,"shortable":0,"etf":0,"ttmEps":-6.1778,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1783301400000},"marketStatusCode":5,"adr":0,"adjPreClose":12.17,"symbolType":"stock","openAndCloseTimeList":[[1783042200000,1783049400000],[1783054800000,1783062000000]],"highLimit":13.39,"lowLimit":10.95,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":2393789747,"isCdr":false,"pbRate":1.89,"roa":"--","roe":"--","epsLYR":-6.1506,"committee":0.341114,"marketValue":29132000000,"turnoverRate":0.0178,"status":2,"floatMarketCap":17212000000},"requestUrl":"/m/hq/s/300122","defaultTab":"news","newsList":[{"id":"2648578776","title":"智飞生物：公司持续加快产品创新，强化核心竞争力","url":"https://stock-news.laohu8.com/highlight/detail?id=2648578776","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648578776?lang=zh_cn&edition=full","pubTime":"2026-07-03 17:06","pubTimestamp":1783069568,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物07月03日在投资者关系平台上答复投资者关心的问题。自去年以来，公司采取一系列措施促进公司生产经营稳健发展。公司持续加快产品创新，强化核心竞争力；优化市场策略，强化商业推广；提升治理水平，扎实做好质量管理，夯实企业发展根基。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070300030926.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2148510915.USD","LU2580892862.HKD","BK0239","BK0188","300122","LU1328615791.USD","LU1064131003.USD","BK0046","LU2580892789.USD","LU1064130708.USD","BK0077","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648965735","title":"智飞生物：公司2026年半年度报告预约于2026年8月18日披露","url":"https://stock-news.laohu8.com/highlight/detail?id=2648965735","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648965735?lang=zh_cn&edition=full","pubTime":"2026-07-03 17:01","pubTimestamp":1783069286,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物07月03日在投资者关系平台上答复投资者关心的问题。与此同时，公司股票从最高点231元算起，6年跌幅近97%在5000多只股票里面跌幅第一，且股价一直破位下跌创新低。请问：公司今年8月份是否能正常出半年报，是否半年报后面临摘牌风险？！智飞生物回复：你好，公司2026年半年度报告预约于2026年8月18日披露，公司经营业绩请持续关注公司的定期报告。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070300030797.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2580892862.HKD","LU2580892789.USD","300122","LU1328615791.USD","BK0188","LU2148510915.USD","LU1064131003.USD","BK0239","LU1064130708.USD","BK0077","BK0046","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648652079","title":"智飞生物：公司已经根据法规要求制定了《市值管理制度》","url":"https://stock-news.laohu8.com/highlight/detail?id=2648652079","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648652079?lang=zh_cn&edition=full","pubTime":"2026-07-03 16:57","pubTimestamp":1783069061,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物07月03日在投资者关系平台上答复投资者关心的问题。投资者提问：根据《上市公司监管指引第10号》第十四条：主要指数成份股公司——必须制定市值管理制度；长期破净公司——必须披露估值提升计划。公司市值屡创新低，管理层却借口二级市场的波动，这明显是经营不善造成。公司通过完善公司治理、改善经营管理，实现公司稳健可持续发展。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070300030645.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2148510915.USD","BK0239","LU2580892862.HKD","300122","LU2580892789.USD","BK0188","LU1328615791.USD","LU1064130708.USD","BK0077","LU1064131003.USD","BK0046","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648434652","title":"智飞生物：自去年以来，公司采取一系列措施促进公司生产经营稳健发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2648434652","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648434652?lang=zh_cn&edition=full","pubTime":"2026-07-03 16:48","pubTimestamp":1783068529,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物07月03日在投资者关系平台上答复投资者关心的问题。而公司最近2年通过互动易回答投资者的提问时，总是说公司生产经营一切正常。公司生产经营正常，为啥公司股票6年跌幅近97%？自去年以来，公司采取一系列措施促进公司生产经营稳健发展。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070300030386.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","LU1064131003.USD","LU1328615791.USD","LU2580892789.USD","BK0196","BK0239","300122","LU2580892862.HKD","LU1064130708.USD","BK0188","LU2148510915.USD","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646035548","title":"智飞生物（300122）披露控股股东部分股份补充质押公告，6月26日股价下跌5.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2646035548","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646035548?lang=zh_cn&edition=full","pubTime":"2026-06-26 17:50","pubTimestamp":1782467459,"startTime":"0","endTime":"0","summary":"截至2026年6月26日收盘，智飞生物报收于11.38元，较前一交易日下跌5.17%，最新总市值为272.41亿元。公告显示，公司控股股东蒋仁生将其持有的公司45,000,000股股份进行补充质押，占其所持股份比例3.88%，占公司总股本比例1.88%。质押股份性质为董事锁定股，质权人为重庆农村商业银行股份有限公司，质押起始日为2026年6月24日，到期日为2030年11月7日。本次质押后，蒋仁生累计质押股份184,350,000股，占其所持股份比例15.90%，占公司总股本比例7.70%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062600033094.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","LU1328615791.USD","LU2148510915.USD","300122","BK0077","BK0046","LU2580892789.USD","BK0196","LU1064131003.USD","LU1064130708.USD","LU2580892862.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646586703","title":"6月26日智飞生物跌5.17%，疫苗ETF嘉实基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2646586703","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646586703?lang=zh_cn&edition=full","pubTime":"2026-06-26 16:55","pubTimestamp":1782464129,"startTime":"0","endTime":"0","summary":"证券之星消息，6月26日智飞生物跌5.17%创60日新低，收盘报11.38元，换手率1.76%，成交量24.87万手，成交额2.9亿元。疫苗ETF嘉实目前规模为2.25亿元，最新净值0.6065，较上一交易日下跌0.21%，近一年上涨13.79%。疫苗ETF嘉实的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062600030722.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2148510915.USD","LU2580892789.USD","BK0046","LU1328615791.USD","BK0239","300122","LU1064131003.USD","BK0188","BK0077","562860","BK0196","LU1064130708.USD","LU2580892862.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645155050","title":"股市必读：智飞生物（300122）6月18日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2645155050","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645155050?lang=zh_cn&edition=full","pubTime":"2026-06-22 02:55","pubTimestamp":1782068110,"startTime":"0","endTime":"0","summary":"截至2026年6月18日收盘，智飞生物报收于12.21元，下跌3.17%，换手率1.8%，成交量25.43万手，成交额3.15亿元。董秘最新回复投资者： 请问董秘，公司是否涉及销售医疗器械相关产品？董秘： 您好，截至2026年6月10日，公司普通股股东人数为114,160，谢谢！该疫苗用于预防婴幼儿及儿童轮状病毒感染引起的急性胃肠炎，采用注射途径免疫，具有免疫原性稳定、持久等特点。目前该事项对公司近期业绩无重大影响，后续进展存在不确定性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062200001026.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","LU1064131003.USD","BK0196","LU1064130708.USD","LU2580892789.USD","BK0239","LU2580892862.HKD","BK0077","BK0188","LU1328615791.USD","300122","LU2148510915.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644706251","title":"智飞生物：目前该计划正常存续中并且为公司股东","url":"https://stock-news.laohu8.com/highlight/detail?id=2644706251","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644706251?lang=zh_cn&edition=full","pubTime":"2026-06-18 16:45","pubTimestamp":1781772320,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物(300122)06月18日在投资者关系平台上答复投资者关心的问题。投资者提问：截至26年6月12日，员工持股计划中的迎水合力9号、8号私募基金是否仍存续？仍为公司股东？智飞生物回复：您好，公司员工持股计划由其管理委员会负责日常管理事宜，目前该计划正常存续中并且为公司股东。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061800029002.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0188","LU1064130708.USD","LU2580892862.HKD","300122","BK0077","BK0196","LU2580892789.USD","LU1328615791.USD","BK0239","LU1064131003.USD","LU2148510915.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644069077","title":"智飞生物：公司积极响应国家号召推进互联网+医疗服务","url":"https://stock-news.laohu8.com/highlight/detail?id=2644069077","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644069077?lang=zh_cn&edition=full","pubTime":"2026-06-18 16:42","pubTimestamp":1781772136,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物(300122)06月18日在投资者关系平台上答复投资者关心的问题。投资者提问：请问董秘，子公司智飞互联网科技公司主要业务覆盖哪些科技创新项目？请详细介绍一下智飞生物回复：您好，公司积极响应国家号召推进互联网+医疗服务，依托智飞互联网科技有限公司开展相应的技术服务。公司子公司的经营范围请您查阅国家企业信用信息公示系统。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061800028915.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300122","BK0188","BK0077","LU1064130708.USD","BK0239","LU2580892789.USD","LU2580892862.HKD","LU1328615791.USD","BK0046","BK0196","LU2148510915.USD","LU1064131003.USD","159792","160636"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644706906","title":"智飞生物：公司的在售产品有ACYW135多糖疫苗、23价肺炎疫苗、四价流感疫苗、九价HPV疫苗、重组带状疱疹疫苗等产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2644706906","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644706906?lang=zh_cn&edition=full","pubTime":"2026-06-18 16:39","pubTimestamp":1781771975,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物(300122)06月18日在投资者关系平台上答复投资者关心的问题。投资者提问：请问董秘，公司是否涉及销售医疗器械相关产品？智飞生物回复：您好，公司的在售产品有ACYW135多糖疫苗、23价肺炎疫苗、四价流感疫苗、九价HPV疫苗、重组带状疱疹疫苗等产品，详情请查阅公司的定期报告。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061800028834.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","159646","BK0188","BK0239","LU1064130708.USD","LU2148510915.USD","LU2580892862.HKD","BK0046","LU2580892789.USD","LU1328615791.USD","BK0196","LU1064131003.USD","300122"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644053047","title":"智飞生物(300122.SZ)：重组轮状病毒亚单位疫苗(大肠杆菌)临床试验申请获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2644053047","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644053047?lang=zh_cn&edition=full","pubTime":"2026-06-18 16:16","pubTimestamp":1781770611,"startTime":"0","endTime":"0","summary":"智通财经APP讯，智飞生物 发布公告，公司于近日获悉，由全资子公司北京智飞绿竹生物制药有限公司研发的重组轮状病毒亚单位疫苗获得国家药品监督管理局药物临床试验申请受理通知书。智飞绿竹研发的重组轮状病毒亚单位疫苗用于预防婴幼儿及儿童轮状病毒感染引起的急性胃肠炎。该疫苗临床试验申请获得受理，是公司聚焦创新技术、增强核心攻关的成果。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1456097.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2580892862.HKD","300122","LU2580892789.USD","LU1064130708.USD","159646","BK0196","LU2148510915.USD","BK0239","BK0077","BK0046","LU1328615791.USD","BK0188","LU1064131003.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641116768","title":"智飞生物：截至2026年5月29日，公司普通股股东人数为115,077","url":"https://stock-news.laohu8.com/highlight/detail?id=2641116768","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641116768?lang=zh_cn&edition=full","pubTime":"2026-06-05 17:03","pubTimestamp":1780650187,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物(300122)06月05日在投资者关系平台上答复投资者关心的问题。投资者提问：截至5月30日，股东总人数是多少？智飞生物回复：您好，截至2026年5月29日，公司普通股股东人数为115,077，谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060500028988.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2148510915.USD","BK0239","LU2580892862.HKD","300122","LU2580892789.USD","BK0188","LU1328615791.USD","LU1064130708.USD","BK0077","LU1064131003.USD","BK0046","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641116782","title":"智飞生物：2025年度研发投入达14.36亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2641116782","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641116782?lang=zh_cn&edition=full","pubTime":"2026-06-05 17:01","pubTimestamp":1780650082,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物06月05日在投资者关系平台上答复投资者关心的问题。公司目前的经营状况，是否还能应对在此期间出现的任何突发情况？智飞生物回复：您好，公司持续开展创新研发，2025年度研发投入达14.36亿元，确保在研管线高效推进。目前，公司在研管线共41项产品，其中五款产品已提交上市申请，十余款产品正同步开展临床研究。公司稳步推进自主产品研发上市，持续控制经营风险，促进公司实现可持续发展，谢谢！","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060500028965.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2580892789.USD","LU1328615791.USD","BK0239","BK0077","300122","LU2148510915.USD","LU2580892862.HKD","BK0188","BK0046","BK0196","LU1064131003.USD","LU1064130708.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641143116","title":"智飞生物：公司自去年以来采取一系列措施促进公司生产经营稳健发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2641143116","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641143116?lang=zh_cn&edition=full","pubTime":"2026-06-05 16:51","pubTimestamp":1780649471,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物06月05日在投资者关系平台上答复投资者关心的问题。投资者提问：根据公司发布的公告，公司2025年一季报亏损3.05亿元，到了2025年底，全年亏损超147亿元。从这个数据可以看出，公司季度亏损明显加大。公司2026年的经营业绩请您持续关注公司的信息披露，谢谢！","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060500028620.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","LU1328615791.USD","LU2148510915.USD","300122","BK0077","BK0046","LU2580892789.USD","BK0196","LU1064131003.USD","LU1064130708.USD","LU2580892862.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641161181","title":"智飞生物：防未病治已病，守护人类健康","url":"https://stock-news.laohu8.com/highlight/detail?id=2641161181","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641161181?lang=zh_cn&edition=full","pubTime":"2026-06-05 16:51","pubTimestamp":1780649465,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物(300122)06月05日在投资者关系平台上答复投资者关心的问题。投资者提问：请问董秘，公司今后是想发展成为民族医药企业巨头（像默沙东，礼来，诺和诺德），去逐渐占领全球医药市场。还是希望成为外资入股的中外合资医药企业？请详细回答智飞生物回复：您好，公司秉持“防未病治已病，守护人类健康”的使命，创新研发，深耕市场，加速推动优质产品惠及民众。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060500028615.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2148510915.USD","BK0239","BK0188","LU1328615791.USD","300122","BK0077","LU2580892789.USD","BK0046","LU2580892862.HKD","BK0196","LU1064130708.USD","LU1064131003.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641611663","title":"智飞生物：公司利拉鲁肽注射液、德谷胰岛素注射液两款产品处于上市审评阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2641611663","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641611663?lang=zh_cn&edition=full","pubTime":"2026-06-05 16:48","pubTimestamp":1780649295,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物06月05日在投资者关系平台上答复投资者关心的问题。公司利拉鲁肽注射液、德谷胰岛素注射液两款产品处于上市审评阶段，司美格鲁肽注射液（降糖）已完成Ⅲ期临床试验，司美格鲁肽注射液（减重）正处于Ⅲ期临床试验阶段，公司持续推进相关工作。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060500028550.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300122","BK0188","BK0077","LU1064130708.USD","BK0239","LU2580892789.USD","LU2580892862.HKD","LU1328615791.USD","BK0196","BK0046","LU2148510915.USD","LU1064131003.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641165851","title":"智飞生物：公司以“技术&市场”双轮驱动发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2641165851","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641165851?lang=zh_cn&edition=full","pubTime":"2026-06-05 16:42","pubTimestamp":1780648934,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物(300122)06月05日在投资者关系平台上答复投资者关心的问题。投资者提问：请问董秘，股价越跌，消费者越恐惧，产品越滞销，这是否是一个恶性循环？如果不是，请用详细销售数据分析回答，谢谢智飞生物回复：您好，公司以“技术&市场”双轮驱动发展，加速推进自研产品上市，目前已有五个产品处于上市审评阶段；优化市场推广策略，强化市场宣传推广，逐步实现公司经营面企稳向好。公司的经营业绩请持续关注公司披露的定期报告。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060500028384.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2148510915.USD","LU2580892862.HKD","BK0239","BK0188","300122","LU1328615791.USD","LU1064131003.USD","BK0046","LU2580892789.USD","LU1064130708.USD","BK0077","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640865911","title":"智飞生物（300122）披露2025年年度股东会决议公告，6月2日股价下跌2.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2640865911","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640865911?lang=zh_cn&edition=full","pubTime":"2026-06-02 17:43","pubTimestamp":1780393389,"startTime":"0","endTime":"0","summary":"截至2026年6月2日收盘，智飞生物报收于13.33元，较前一交易日下跌2.7%，最新总市值为319.09亿元。该股当日开盘13.7元，最高13.71元，最低13.29元，成交额达2.03亿元，换手率为1.07%。近日，重庆智飞生物制品股份有限公司披露《2025年年度股东会决议公告》。公告显示，公司于2026年6月1日召开2025年年度股东会，会议由董事长蒋仁生主持，采用现场与网络投票结合方式召开。出席会议股东共854人，代表股份1,408,540,200股，占公司有表决权股份总数的58.8414%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060200034546.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1328615791.USD","LU1064130708.USD","BK0046","BK0239","LU1064131003.USD","BK0196","300122","LU2580892862.HKD","BK0188","BK0077","LU2580892789.USD","LU2148510915.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640598513","title":"股市必读：智飞生物（300122）5月29日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2640598513","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640598513?lang=zh_cn&edition=full","pubTime":"2026-06-01 03:39","pubTimestamp":1780256350,"startTime":"0","endTime":"0","summary":"截至2026年5月29日收盘，智飞生物报收于13.59元，下跌0.88%，换手率1.53%，成交量21.58万手，成交额2.98亿元。董秘最新回复投资者： 请问董秘，员工持股现在亏损比例是多少？请详细回答董秘： 您好，根据相关规定，公司员工持股计划由其管理委员会负责日常管理事宜，目前该计划正常存续中。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060100001544.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2580892789.USD","LU1328615791.USD","BK0239","BK0077","300122","LU2148510915.USD","LU2580892862.HKD","BK0188","BK0046","BK0196","LU1064131003.USD","LU1064130708.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639731596","title":"智飞生物：15价肺炎结合疫苗目前处于上市审评阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2639731596","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639731596?lang=zh_cn&edition=full","pubTime":"2026-05-29 22:18","pubTimestamp":1780064304,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物(300122)05月29日在投资者关系平台上答复投资者关心的问题。投资者提问：1.15价肺炎疫苗获批进展，大约什么时间知道能批下来2.司美格鲁肽临床进展到哪个阶段3.公司目前经营状况智飞生物回复：您好，公司15价肺炎结合疫苗目前处于上市审评阶段，司美格鲁肽（降糖）已经完成Ⅲ期临床试验，司美格鲁肽（减重）正处于Ⅲ期临床试验阶段，相关产品的研发信息请您持续关注公司的信息披露。公司正持续加快产品创新，推动在研管线进展，强化市场推广和宣传，以实现公司稳健发展。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052900046243.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2580892789.USD","LU1328615791.USD","BK0239","BK0077","300122","LU2148510915.USD","LU2580892862.HKD","BK0188","159646","BK0046","BK0196","LU1064131003.USD","LU1064130708.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1783176567975,"stockEarnings":[{"period":"1week","weight":0.0694},{"period":"1month","weight":-0.0551},{"period":"3month","weight":-0.2061},{"period":"6month","weight":-0.3551},{"period":"1year","weight":-0.3866},{"period":"ytd","weight":-0.3551}],"compareEarnings":[{"period":"1week","weight":0.0041},{"period":"1month","weight":-0.0099},{"period":"3month","weight":0.0421},{"period":"6month","weight":0.0188},{"period":"1year","weight":0.1683},{"period":"ytd","weight":0.0188}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"重庆智飞生物制品股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"114049人(较上一季度减少0.10%)","perCapita":"12400股","listingDate":"2010-09-28","address":"重庆市两江新区庆云路1号50层","registeredCapital":"239378万元","survey":" 重庆智飞生物制品股份有限公司的主营业务是疫苗、生物制品研发、生产、销售、推广、配送及进出口。公司的主要产品是盟威克、盟纳康、喜菲贝、盟纳克、智克威得、宜卡、微卡、优威克、四价流感病毒裂解疫苗、佳达修、佳达修9、乐儿德、纽莫法、维康特、欣安立适。","listedPrice":37.98},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"智飞生物(300122)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供智飞生物(300122)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"智飞生物,300122,智飞生物股票,智飞生物股票老虎,智飞生物股票老虎国际,智飞生物行情,智飞生物股票行情,智飞生物股价,智飞生物股市,智飞生物股票价格,智飞生物股票交易,智飞生物股票购买,智飞生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"智飞生物(300122)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供智飞生物(300122)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}